Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Standard Dose
400MG;300MG;300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 213038 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 400MG;300MG;300MG Sponsor LAURUS Submission history Latest submission status date: 2020-05-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 213038 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 400MG;300MG;300MG Sponsor LAURUS Submission history Latest submission status date: 2020-05-14 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.